Amylyx Pharmaceuticals Strengthens Leadership Team with the Appointments of Chief Medical Officer, Chief Commercial Officer and Global Head, Supply Chain

“We are thrilled to welcome Patrick, Margaret and Tom to the Amylyx team, with their decades of experience spanning clinical development all the way through launch and commercialization,” said Joshua Cohen, chief executive officer and co-founder of Amylyx. “With two Phase II clinical trials underway, expanding our leadership team helps us progress toward our mission to bring new therapeutic options rapidly to the people suffering from neurodegenerative diseases.”

Dr. Yeramian brings more than 30 years of pharmaceutical industry experience to Amylyx. Prior to joining Amylyx as chief medical officer, he served as consulting medical director for the company, where he supported the pre-IND and IND filings of AMX0035, the company’s proprietary therapeutic, for the treatment of amyotrophic lateral sclerosis and Alzheimer’s disease and oversaw the design and execution of both clinical trials. Previously he served as chief medical officer at Viragen, Inc., where he was responsible for the development of global clinical and regulatory strategies and for the implementation of clinical programs worldwide. Throughout his career, Dr. Yeramian supervised the clinical development of new drugs, biopharmaceuticals, vaccines and cellular therapy agents. He held prominent roles in the approval of drug, biologic and devices by the FDA and EMA. Additionally, he was involved in the opening of more than 20 INDs and IMPDs. He also previously served as medical director of the Vaccine and Gene Therapy Institute of Florida. Dr. Yeramian holds a medical degree from the University of Paris together with a Master of Clinical Science in experimental oncology and graduate degree in molecular virology. He received his Master of Business Administration from Rutgers University.

Margaret Olinger joins Amylyx after more than a decade at Alexion Pharmaceuticals, where she helped build and lead some of the most successful commercial launches and operations throughout the U.S. and globally for therapies addressing unmet needs in rare and ultra-rare diseases, including Strensiq^® and Soliris^®. During Mrs. Olinger’s tenure at Alexion, she served in various commercial leadership roles, most recently as vice president, head of global Strensiq^® therapeutic area, and previously held positions including vice president, U.S. complement business unit leader; vice president, global hematology therapeutic area; vice president, global PNH therapeutic area; and vice president, U.S. and global marketing, a role in which she supported commercialization of Soliris^® for PNH across all markets. Prior to Alexion, Ms. Olinger spent nearly 20 years at Bayer Healthcare, serving in various leadership and commercial positions, which culminated in her role as director, executive operations. Mrs. Olinger received a Bachelor of Science in business administration from Albertus Magnus College and a Master of Business Administration from the University of New Haven.

Tom Holmes brings more than 25 years of leadership experience in supply chain, biopharmaceutical manufacturing and program management. Prior to joining Amylyx, Mr. Holmes was the senior director of external manufacturing at Biogen Inc., a role he held for 10 years. As senior director, Mr. Holmes managed Biogen’s global external manufacturing network and was responsible for driving supply contracting decisions for 11 commercial assets and more than 42 new molecular entities in various stages of clinical development. Mr. Holmes held several positions at Biogen beginning in 1994, including planning & logistics, program management, launch lead, and manufacturing. Mr. Holmes received a Bachelor of Science in Business Administration with a concentration in Management from Salem State University.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. The company’s therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that act synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models. This press release and further information about Amylyx can be found at: www.amylyx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005446/en/